2 results
Approved WMORecruiting
The primary objective of the study is to determine the efficacy of AP26113, as evidenced by objective response rate, in patients with ALK positive locally advanced or metastatic NSCLC whose disease has progressed on therapy with crizotinib.
Approved WMOCompleted
The primary objectives are to establish dose-response relationship for 2% transdermal testosterone (TostranĀ®) gel to achieve total testosterone serum concentrations between 1.5-2.5 nmol/l in transgender women after vaginoplasty and to assess sideā¦